News | ESC | July 21, 2020

European Society of Cardiology Announces Late-Breaking Study Presentations at its 2020 Virtual Congress

The European Society of Cardiology (ESC) will host several Hot Lines sessions that will include some of the latest clinical science presentations in cardiology at the 2020 annual congress digital meeting. The meeting has gone virtual due to the ongoing pandemic. 

The European Society of Cardiology (ESC) will host several Hot Lines sessions that will include some of the latest clinical science presentations in cardiology at the 2020 annual congress digital meeting. The meeting has gone virtual due to the ongoing pandemic. 

The congress is planned for Saturday, Aug. 29, through Tuesday Sept. 1, 2020. Read more on ECS's move to a digital meeting.

ESC said the event will include live presentations and panel discussions. To find out more, visit the event website at https://www.escardio.org/Congresses-&-Events/ESC-Congress

Hot Line sessions below are all in Central European Summer Time (CEST):

Saturday, Aug. 29
   • Hot Line 1: EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes. 14:30 - 15:00
   • Hot Line 2: EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy. 15:30 - 16:00
   • Hot Line 3: EAST – AFNET 4: Effects of Early Rhythm Control Therapy in Patients with Atrial Fibrillation. 17:00 - 17:30

 

Sunday, Aug. 30
   • Hot Line 4: ATPCI - Trimetazidine in Angina Patients with Recent Successful Percutaneous Coronary Intervention: a Randomized, Double-Blind, Placebo-Controlled Trial. 14:00 - 14:30
   • Hot Line 5: POPULAR TAVI -Aspirin With or Without Clopidogrel. 14:30 - 15:00
   • Hot Line 6: PARALLAX: Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF. 16:30 - 17:00

 

 

Monday, Aug. 31
   • Hot Line 7: LoDoCo2 Low-Dose Colchicine in Coronary Disease. 14:00 - 14:30
   • Hot Line 8: HOME-PE - Hospitalisation or Outpatient Management of PE Patients - HESTIA vs. Simplified PESI. 14:30 - 15:00
   • Hot Line 9: BPLTTC - Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure. 16:30 - 17:00

 

Tuesday, Sept. 1
   • Hot Line 10: BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19. 14:00 - 14:30
   • Hot Line 11: IMPACT-Afib Implementation of Stroke Prevention in Atrial Fibrillation. 14:30 - 15:00
   • Hot Line 12: REALITY - A Trial of Transfusion Strategies for Myocardial Infarction and Anemia. 16:30 - 17:00

 

Other ESC Clinical Studies

Study Shows Severe Fainting Can Be Treated with Cardiac Pacing Supported by Closed Loop Stimulation

Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study
 

Read the article Highlights From the 2019 ESC Congress.
 


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now